At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) provides an overview on current strategies in kidney cancer management.
Focus in this field is moving away from VEGF and mTOR inhibitors. Current topics of interest include novel targets, acquired mechanisms of therapy resistance and immune checkpoint inhibitors. In lieu of biomarker availability for predicting therapy response, genetic sequencing methods are used to guide research in new combination therapies.